
GLP-1 Drugs May Reverse Biological Aging by 2-3 Years, New Data Suggests
Eli Lilly and Novo Nordisk presented data at the Aging Research & Drug Discovery conference showing that their GLP-1 weight-loss drugs, semaglutide and tirzepatide, may reverse biological aging by two to three years in patients with obesity or type 2 diabetes. Using molecular 'aging clocks,' researchers found that these medications slow the molecular time of aging in various organs, with some clocks showing a reduction of up to four years. While the findings are promising, they are based on unreviewed data and do not yet prove that the drugs will extend lifespan or improve health outcomes in healthy populations. Further research is needed to determine the long-term effects of these drugs on aging.




